Also trades as: NVV1.F (FSX) · $vol 0M
NVAX NASDAQ
Novavax, Inc.
1W: -12.3%
1M: -7.2%
3M: +36.5%
YTD: +40.5%
1Y: +17.6%
3Y: +55.8%
5Y: -93.8%
$10.02
+0.62 (+6.60%)
Weekly Expected Move ±16.8%
$6
$8
$10
$11
$13
Credit Risk of going bust: higher than 66% of companies Debt: 15.2% of company value Bonds: none of note held by US funds details ▾
Of US companies ranked in the middle of the pack, about 1 in 580 filed for bankruptcy within a year (2020-2025).
If the stock fell to about $0.23 (down 98%), Novavax, Inc. would be worth roughly what it owes.
Total debt $295.6M against a stock market value of $1.65B.
Distance to default 3.70 (Merton model): prices to 2026-10-27, balance sheet 2026-06-30, debt counted $144.9M (short-term plus half of long-term), stock volatility 69.0%; Altman Z'' -14.52. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
If the stock fell to about $0.23 (down 98%), Novavax, Inc. would be worth roughly what it owes.
Total debt $295.6M against a stock market value of $1.65B.
Distance to default 3.70 (Merton model): prices to 2026-10-27, balance sheet 2026-06-30, debt counted $144.9M (short-term plus half of long-term), stock volatility 69.0%; Altman Z'' -14.52. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Supply Chain Overview
25 relationships25
As Filer
counterparties named
0
As Counterparty
mentioned by others
5
Rel. Types
2021-08-20
Earliest Filing
2026-01-20
Latest Filing
partner: 13
supplier: 4
acquirer: 3
customer: 3
target: 2
Counterparties (Filed by NVAX)
25 relationshipsCompanies named in NVAX's SEC 8-K filings as business counterparties.
| Counterparty | Ticker | Relationship | Summary | Filing Date | SEC |
|---|---|---|---|---|---|
| Pfizer Inc. | PFE | partner | Novavax entered into a License and Option Agreement for Pfizer to research, develop, and commercialize the Matrix-MTM ad | 2026-01-20 | View |
| AstraZeneca Pharmaceuticals LP | AZN | partner | Entered into lease assignment, land sale, and asset purchase agreements with Novavax, Inc. | 2025-10-22 | View |
| Takeda Pharmaceutical Company Limited | TKPHF | partner | Novavax entered into an amended collaboration and exclusive license agreement for vaccine development and commercializat | 2025-05-05 | View |
| Novo Nordisk A/S | — | partner | Signatory to asset purchase agreement | 2024-12-30 | View |
| Novo Nordisk Production Czech s.r.o. | — | acquirer | Purchaser of biologics manufacturing campus in Czech Republic | 2024-12-30 | View |
| Novavax CZ a.s. | NVAX | target | Seller of biologics manufacturing campus in Czech Republic | 2024-12-30 | View |
| Commonwealth of Australia | — | customer | Amendment to Advanced Purchase Agreement for COVID-19 Vaccine delivery and payment credit | 2024-12-18 | View |
| Novavax CZ a.s. | NVAX | target | Seller of biologics manufacturing campus in Czech Republic | 2024-12-04 | View |
| Novo Nordisk Production Czech s.r.o. | — | acquirer | Purchaser of Novavax CZ manufacturing campus assets | 2024-12-04 | View |
| Novo Nordisk A/S | — | acquirer | Co-purchaser of Novavax CZ manufacturing campus assets | 2024-12-04 | View |
| FUJIFILM Diosynth Biotechnologies UK Limited | — | partner | Counterparty in a settlement agreement resolving disputes over manufacturing cancellation payments. | 2024-03-26 | View |
| FUJIFILM Diosynth Biotechnologies USA, Inc. | — | partner | Counterparty in a settlement agreement resolving disputes over manufacturing cancellation payments. | 2024-03-26 | View |
| FUJIFILM Diosynth Biotechnologies Texas, LLC | — | partner | Counterparty in a settlement agreement resolving disputes over manufacturing cancellation payments. | 2024-03-26 | View |
| Serum Institute of India Pvt. Ltd. | — | partner | Counterparty to a license and supply agreement for Matrix-M adjuvant, whose accounts receivable were pledged as security | 2024-02-22 | View |
| Gavi Alliance | — | customer | Counterparty in a termination and settlement agreement regarding an advance purchase agreement for COVID-19 vaccines. | 2024-02-22 | View |
| SK bioscience Co., Ltd. | — | partner | Settlement agreement and equity investment regarding manufacturing cancellation and license terms | 2023-08-08 | View |
| BMC Inc. | — | partner | Designated to produce bulk antigen for Vaccine doses in 2024 and 2025 under the amended agreement. | 2023-07-07 | View |
| FUJIFILM Diosynth Biotechnologies Texas, LLC | — | supplier | Counterparty in settlement agreement regarding termination of manufacturing activity and payment of $185 million. | 2022-10-06 | View |
| FUJIFILM Diosynth Biotechnologies USA, Inc. | — | supplier | Counterparty in settlement agreement regarding termination of manufacturing activity and payment of $185 million. | 2022-10-06 | View |
| FUJIFILM Diosynth Biotechnologies UK Limited | — | supplier | Counterparty in settlement agreement regarding termination of manufacturing activity and payment of $185 million. | 2022-10-06 | View |
| Advanced Technology International | — | partner | Consortium management firm acting on behalf of the Medical CBRN Defense Consortium for vaccine delivery partnership | 2022-07-11 | View |
| Serum Institute of India Private Limited | — | supplier | Manufacturing partner for the NVX-CoV2373 vaccine product | 2022-07-11 | View |
| SK bioscience Co., Ltd. | — | partner | Novavax amended a collaboration and license agreement granting SK bioscience exclusive rights to develop, manufacture, a | 2021-12-30 | View |
| European Commission | — | customer | Advanced purchase agreement for COVID-19 vaccine supply and development | 2021-08-20 | View |
| Gavi, the Vaccine Alliance | — | partner | Existing advance purchase agreement holder | 2021-08-20 | View |
Recent 8-K Filings (20)
| Filing Date | Description | Type | SEC |
|---|---|---|---|
| 2026-08-06 | Earnings Release; Exhibits | View | |
| 2026-06-23 | Shareholder Vote | View | |
| 2026-05-06 | Earnings Release; Exhibits | View | |
| 2026-02-26 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2026-01-20 | Entry into Material Definitive Agreement | Agreement | View |
| 2026-01-12 | Results of Operations and Financial Condition; Regulation FD Disclosure; Financial Statements and Ex | View | |
| 2025-11-06 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2025-11-04 | Regulation FD Disclosure; Other Events; Financial Statements and Exhibits | View | |
| 2025-10-22 | Entry into Material Definitive Agreement; Material Impairments; Other Events; Financial Statements a | Agreement | View |
| 2025-10-07 | Regulation FD Disclosure; Other Events; Financial Statements and Exhibits | View | |
| 2025-08-27 | Regulation FD Disclosure; Other Events; Financial Statements and Exhibits | View | |
| 2025-08-27 | Entry into Material Definitive Agreement; Creation of Direct Financial Obligation; Unregistered Sale | Agreement | View |
| 2025-08-21 | Entry into Material Definitive Agreement; Unregistered Sales of Equity Securities; Other Events; Fin | Agreement | View |
| 2025-08-06 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2025-06-24 | Submission of Matters to a Vote of Security Holders | View | |
| 2025-06-11 | Regulation FD Disclosure; Financial Statements and Exhibits | View | |
| 2025-05-27 | Departure/Election of Directors; Appointment of Officers | View | |
| 2025-05-19 | Regulation FD Disclosure; Other Events | View | |
| 2025-05-08 | Results of Operations and Financial Condition | View | |
| 2025-05-05 | Entry into Material Definitive Agreement | Agreement | View |
Data extracted from SEC EDGAR 8-K filings using NLP. Relationships are as disclosed in filing text.
Covers 2021–2026. View on SEC EDGAR